Processing

Please wait...

Settings

Settings

Goto Application

1. WO2015138889 - COMPOSITIONS AND METHODS FOR DIAGNOSING BARRETT'S ESOPHAGUS STAGES

Publication Number WO/2015/138889
Publication Date 17.09.2015
International Application No. PCT/US2015/020436
International Filing Date 13.03.2015
IPC
G01N 33/574 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
CPC
G01N 2800/06
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
06Gastro-intestinal diseases
G01N 2800/56
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
56Staging of a disease; Further complications associated with the disease
G01N 33/577
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
577involving monoclonal antibodies ; binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens;
G01N 33/6893
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6893related to diseases not provided for elsewhere
Applicants
  • THE PENN STATE RESEARCH FOUNDATION [US]/[US]
Inventors
  • STAIRS, Douglas
  • MASSE, Julie
Agents
  • WATT, Rachel, S.
Priority Data
61/952,56813.03.2014US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS AND METHODS FOR DIAGNOSING BARRETT'S ESOPHAGUS STAGES
(FR) COMPOSITIONS ET MÉTHODES DE DIAGNOSTIC DE STADES D'ENDOBRACHYOESOPHAGE
Abstract
(EN) Provided is an immunohistochemistry panel that facilitates the discrimination between the early and late stages of Barret's esophagus in a method that involves testing a biological sample for expression of CDX2, pl20ctn, c-Myc and Jagged1 proteins, comparing the amount of the CDX2, pl20ctn, c-Myc and Jagged1 proteins to reference values, and providing a diagnosis of, or aiding in a physician's diagnosis, of the individual as having high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) by determining less CDX2 protein relative to non-dysplastic Barrett's esophagus (ND-BE) and low-grade dysplasia (LGD) CDX2 protein values, but more CDX2 protein than a normal CDX2 protein reference value; and less pl20ctn protein relative to ND-BE, LGD and normal 120ctn protein reference values; and increased c-Myc protein relative to ND-BE and LGD protein reference values; and increased Jagged1 protein relative to normal and ND-BE Jagged1 protein reference values. Kits for making the protein determinations are also provided.
(FR) La présente invention se rapporte à un panel d'immunohistochimie qui facilite la discrimination entre les stades précoces et tardifs d'endobrachyoesophage selon une méthode qui consiste à tester un échantillon biologique en vue de déterminer l'expression des protéines CDX2, pl20ctn, c-Myc et Jagged1, à comparer la quantité des protéines CDX2, pl20ctn, c-Myc et Jagged1 à des valeurs de référence, et à fournir un diagnostic, ou à faciliter le diagnostic d'un médecin, selon lequel l'individu est atteint d'une dysplasie de haut degré de malignité (HGD) ou d'une adénocarcinome de l'œsophage (EAC) en déterminant une quantité inférieure de protéine CDX2 par rapport aux valeurs protéiques CDX2 d'endobrachyoesophage non dysplasique (ND-BE) et de dysplasie de faible degré de malignité (LGD), mais une quantité supérieure de protéine CDX2 par rapport à une valeur de référence de protéine CDX2 normale; et une quantité inférieure de protéine pl20ctn par rapport aux valeurs de référence de protéine 120ctn ND-BE et LGD normales; et une quantité accrue de protéine c-Myc par rapport aux valeurs de référence de protéine ND-BE et LGD; et une quantité accrue de protéine Jagged1 par rapport aux valeurs de référence de protéine Jagged1 ND-BE normales. L'invention concerne également des kits permettant d'effectuer les déterminations de protéines.
Related patent documents
Latest bibliographic data on file with the International Bureau